TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06746220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiota sample
Description: Microbiota sample: one sample at inclusion and one sample at the end of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiota sample
Description: Microbiota sample: one sample at inclusion and one sample at the end of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiota sample
Description: Microbiota sample: one sample at inclusion and one sample at the end of the study
Study: NCT05426616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)
Description: A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
Study: NCT06040840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BAX
Description: Injection of 30 mL of lidocaine (10 mg/ml) around the median, radial, ulnar and musculocutaneous nerves.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: Inflation pressure 75 to 100 mmHg above the patient's systolic blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Axillary block with Lidocaine (10 mg/ml).
Study: NCT06746220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiota sample
Description: Microbiota sample: one sample at inclusion and one sample at the end of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary sample
Description: Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.
Study: NCT05045872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domestic polysaccharide superparamagnetic iron oxide nanoparticle
Description: Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
Study: NCT05068713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care + High Target of Mean Arterial Pressure
Description: Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.
Study: NCT06027151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1ml of 1% metronidazole gel
Description: 1ml of 1% metronidazole gel subgingivally at baseline visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1ml of 2% minocycline gel
Description: 1ml of 2% minocycline gel sub gingivally at baseline visit
Study: NCT06746220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary sample
Description: Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary sample
Description: Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salivary sample
Description: Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.
Study: NCT06027151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1ml of combination of 1% metronidazole gel and 2% minocycline
Description: 1ml of the combination of 1% metronidazole gel and 2% minocycline subgingivally at baseline visit
Study: NCT06389318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buccal midazolam +oral placebo syrup
Description: Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline
Description: Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
Study: NCT05426616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)
Description: A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
Study: NCT04783545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX-1005
Description: VLX-1005 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX-1005
Description: VLX-1005 infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study: NCT06502210

Intervention type: PROCEDURE
Intervention: Personalized surgical therapy of neuroblastoma
Description: If the size of the tumor tissue is too large, the doctor gives the patient chemotherapy and then performs surgery to remove the tumor. In this study, the genotypes of children with neuroblastoma are screened by using Deep Sequencing Technology and Third Generation Sequencing Technology, and the treatment will be performed according to different therapeutic modalities.
Study: NCT06040840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WALANT
Description: Preparation of a mixture of 20 ml of lidocaine (10 mg/ml) with epinephrine (0.005 mg/ml) + 3 ml Na bicarbonate (84 mg/ml) + 17 ml sterile normal saline.~The ultrasound probe will be placed to obtain a transverse image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 5 ml of the solution posterior and then anterior to the median nerve under the annular carpal ligament.~Then the ultrasound probe will be placed to obtain a longitudinal image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 15 ml of the solution anterior to the median nerve towards the carpal tunnel.~At last, a local infiltration with 5 ml of the solution will be performed around the surgical incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine + Epinephrine
Description: WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
Study: NCT05467371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Action Plan
Description: The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safe Kids Home Safety Checklist
Description: Safe Kids created a home safety checklist to help keep kids safe, room by room.
Study: NCT05679518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ConquerFear intervention
Description: ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM intervention
Description: CALM is a semi-structured, manualized, individual psychotherapy intervention designed for patients with advanced cancer. It includes 3-6 individual therapy sessions, with each approximately lasts 45-60 minutes, delivered over 3-6 months. The sessions cover 4 domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. All modules will be addressed with each patient, but the sequencing and time devoted to each domain can be varied, based on the concerns that are most relevant to each patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Cancer Care
Description: Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
Study: NCT06306989

Intervention type: DRUG
Intervention: Letermovir
Description: Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.

Intervention type: DRUG
Intervention: Letermovir
Description: Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.
Study: NCT05879601

Intervention type: OTHER
Group type: OTHER
Intervention: immediate orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed orthodontic retainer delivery.
Description: post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
Study: NCT06747104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Performing manipulations without a two-second preliminary tension of the joint capsule in the shoulder and elbow joints.
Study: NCT06746454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Instructed Training Group
Description: Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included a landing error scoring system, knee position error sense, and frontal plane projection angle. After the pre-test measurements, 2 training packages with special instructions were performed for the video instructed training (VIT) group. The special instruction for the VIT group included a previously prepared video of a successful vertical jump landing task. This video was shown to the VIT group. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Combined Focus Instructed Training Group
Description: Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included landing error scoring system, knee position error sense, and frontal plane projection angle. After the pretest measurements, 2 training packages with specific instructions were performed for the CSE group. The special instruction given to the CSE group consisted of the following sentence, which included the both internal and external focus of attention; focus on how hard you push yourself off the ground and how fast you straighten your knees during this push-off. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases.
Study: NCT06746012

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Participate in think-aloud sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Receive health coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use Healthy Buckeyes app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Watch videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Complete semi-structured interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete semi-structured interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbiit and use exercise bands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive caregiver support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study: NCT06214819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
Description: VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
Study: NCT05166902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lehfilcon A lens)
Description: 1 month
Study: NCT05628571

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Zinc toothpaste
Description: Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride Toothpaste
Description: Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
Study: NCT06214819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
Description: XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
Study: NCT04388228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extended audit and feedback in GPs electronic health record
Description: The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended audit and feedback in GPs electronic health record
Description: The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback.
Study: NCT05879029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.
Description: Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.
Description: Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
Study: NCT05107076

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Echocardiography with color Doppler assessment & Galactin-3 level in blood
Description: * Measurements will be~  1. Pulsed wave (PW) Doppler~ 2. E (early diastolic)/A (late diastolic) - Using PW Doppler~ 3. IVRT (isovolumic relaxation time)~ 4. Deceleration time (DT) - from the peak of E wave to baseline.~ 5. E/e'- PW tissue Doppler imaging (TDI)~ 6. Left atrial volume and left atrial volume index (LAVI)~* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level.
Study: NCT05780073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg
Description: Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
Study: NCT06556511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered with standard therapy in the placebo group for a period of 10 days.
Study: NCT05259358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercises that increase muscular endurance
Study: NCT05661110

Intervention type: OTHER
Intervention: Observational
Description: All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.